RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
In a $220 million agreement, South Korea’s ABL Biotechnologies acquired rights to use WuXi Biologics’ discovery platforms to develop multiple bispecific antibodies including new bispecific antibodies that target a novel immune check point receptor. WuXi Biologics, which will receive the $220 million in a combination of upfront and milestone payments, will also be paid royalties on any commercialized products from the partnership. ABL Bio will use WuXi’s WuXiBody™ and CD3 platforms. The new partnership expands an existing agreement between the two companies announced in November 2018.
Source: China Biotoday
